Cipla Recalls Inhalation Drug in US

1 Minute Read Listen to Article
Share:    

Aug 27, 2025 16:05

x
Cipla recalls over 20,000 packs of Albuterol Sulfate Inhalation Aerosol in the US due to failed stability specifications.
Cipla Recalls Inhalation Drug in US
New Delhi, Aug 27 (PTI) Drug major Cipla is recalling over 20,000 packs of a medication, used to treat asthma and certain types of chronic obstructive pulmonary disease, in the US, according to the US health regulator.

In its latest Enforcement Report, the US Food and Drug Administration (USFDA) stated that Cipla USA, Inc., an arm of the Mumbai-based drug major, is recalling Ibuterol Sulfate Inhalation Aerosol.

The company is recalling 20,352 packs of the inhalation drug due to "Failed Stability Specifications", it stated.


"Out-of-specification results were observed in Induction Port during the analysis of Particle size distribution at the 12-month time point," USFDA added.

Albuterol is used to treat or prevent bronchospasm in patients with asthma, bronchitis, emphysema, and other lung diseases.

New Jersey-based Cipla USA, Inc. initiated the Class III recall on July 24 this year.

As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback